

Neuland Laboratories Limited
Sanali Info Park, 'A' Block,
Ground Floor, 8-2-120/113
Road No. 2, Banjara Hills
Hyderabad, 500 034, AP, India

Tel: 040 30211600 / 23551081
Fax: 040 30211602
Email: neuland@neulandlabs.com
www.neulandlabs.com

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2014

PART - I

Amount in ₹ Lacs

Sl. No.	Particulars	Quarter Ended 30.06.2014 (Unaudited)	Quarter Ended 31.03.2014 (Unaudited)	Quarter Ended 30.06.2013 (Unaudited)	Year Ended 31.03.2014 (Audited)
1	Income from Operations				
	(a) Net Sales / Income from Operations	10,267.45	10,926.25	12,131.84	46,569.33
	(b) Other Operating Income	73.44	116.09	72.08	341.48
	Total Income from Operations (Net)	10,340.89	11,042.34	12,203.92	46,910.81
2	Expenses				
	(a) Consumption of Raw Materials	6,368.23	5,986.13	6,352.93	24,644.22
	(b) Changes in inventories of finished goods and work in process	(922.35)	(348.64)	465.63	12.80
	(c) Employee Benefit Expense	1,054.44	942.66	963.52	3,625.51
	(d) Depreciation	389.90	390.14	365.18	1,493.86
	(e) Manufacturing Expenses	1,241.51	1,312.83	993.61	4,842.24
	(f) Other Expenses	1,165.17	1,330.30	1,368.30	6,506.06
	Total Expenses	9,296.90	9,613.42	10,509.17	41,124.69
3	Profit from Operations before Finance Costs (1-2)	1,043.99	1,428.92	1,694.75	5,786.12
4	Finance Costs	567.82	547.82	590.05	2,363.76
5	Profit / (Loss) before Tax (3-4)	476.17	881.10	1,104.70	3,422.36
6	Tax Expense				
	(a) Current tax	103.90	190.60	210.50	716.70
	(b) Deferred Tax	173.83	22.28	323.60	755.61
	(c) MAT Credit entitlement	(103.90)	(190.60)	(210.50)	(716.70)
7	Net Profit / (Loss) for the period (5-6)	302.34	858.82	781.10	2,666.75
8	Paid-up Equity Share Capital (Face Value ₹10 per share)	772.63	772.63	771.56	772.63
9	Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year				11,392.57
10	Earnings per Share (EPS) (in ₹)				
	(a) Basic	3.95	11.22	10.22	34.87
	(b) Diluted	3.95	11.22	10.21	34.86

PART - II

Sl. No.	Particulars	Quarter Ended 30.06.2014 (Unaudited)	Quarter Ended 31.03.2014 (Unaudited)	Quarter Ended 30.06.2013 (Unaudited)	Year Ended 31.03.2014 (Audited)
A	PARTICULARS OF SHARE HOLDING				
1	Public Shareholding				
	(a) Number of Shares	38,22,899	38,22,899	38,17,199	38,22,899
	(b) Percentage of Shareholding	49.94%	49.94%	49.93%	49.94%
2	Promoters and Promoter Group Shareholding				
	(a) Pledged / Encumbered				
	-Number of Shares	2,00,000	2,00,000	2,00,000	2,00,000
	-Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	5.22%	5.22%	5.22%	5.22%
	-Percentage of Shares (as a % of the total share capital of the Company)	2.61%	2.61%	2.62%	2.61%
	(b) Non-encumbered				
	-Number of Shares	36,32,779	36,32,779	36,27,779	36,32,779
	-Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	94.78%	94.78%	94.78%	94.78%
	-Percentage of Shares (as a % of the total share capital of the Company)	47.45%	47.45%	47.45%	47.45%


B INVESTOR COMPLIANTS

Particulars	Quarter Ended 30.06.2014
Pending at the beginning of the quarter	0
Received during the quarter	9
Disposed off during the quarter	9
Remaining unresolved at the end of the quarter	0

NOTES:

- The above unaudited financial results have been reviewed by the Audit Committee at their meeting held on July 31, 2014, and approved and taken on record at the Board of Directors meeting held on August 1, 2014.
- EPS for the quarters is not annualised.
- The Company's operations are predominantly related to the manufacture of Active Pharmaceutical Ingredients (API). As such there is only one primary reportable segment as per Accounting Standard - AS 17 "Segment Reporting".
- The Board had on July 17, 2014, issued and allotted 2,300 fully paid up equity shares of a face value of ₹10 each, to eligible employees pursuant to exercise of stock options granted under Employee Stock Option Scheme, 2008.
- In accordance with the requirements to Schedule II of the Companies Act, 2013, the Company has re-assessed the useful lives and residual value of the fixed assets and:
 - An amount of ₹98.84 lakhs has been adjusted to the opening balance of Reserves & Surplus in respect of those assets where the useful life exhausted as at April 1, 2014
 - The profit for the quarter has decreased by ₹11.99 lakhs on account higher depreciation due to application of Schedule II.
- Previous quarter / year numbers have been regrouped wherever necessary.

By Order of the Board
For Neuland Laboratories Limited



Dr. D.R. Rao

Chairman & Managing Director

Place: Hyderabad

Date: August 1, 2014